{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-388010","form_type":"8-K","ticker":"WHWK","cik":"0001422142","company_name":"Whitehawk Therapeutics, Inc.","filed_at":"2026-09-10T21:02:18+00:00","discovered_at":"2026-09-10T21:04:00.560729+00:00","generated_at":"2026-09-10T21:04:05.750561+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Whitehawk appoints Vijay Iyengar, MD, to board; board expands to 10","bullets":["Board expanded from 9 to 10; Iyengar appointed Class III director effective Sept 9, 2026, term to 2029 annual meeting.","Iyengar served as EVP at Incyte (INCY) from 2016-2025; led growth from ~$1B to >$4B revenue, launched 5 brands.","As non-employee director, receives $40k annual retainer and initial option grant of 76,080 shares vesting over 3 years.","Press release dated Sept 10, 2026 attached as Exhibit 99.1; no related-party transactions or family relationships."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-388010","json":"https://secwatch.observer/filing/0001193125-26-388010.json","markdown":"https://secwatch.observer/filing/0001193125-26-388010.md","text":"https://secwatch.observer/filing/0001193125-26-388010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422142/000119312526388010/0001193125-26-388010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422142/000119312526388010/d160342d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-10T21:04:05.750561+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0bf2dba42c","claim":"Vijay Iyengar, M.D. was appointed as Class III director at Whitehawk Therapeutics, Inc..","evidence_excerpt":"appointed Vijay Iyengar, M.D. to fill the newly created opening on the Board, effective September 9, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000119312526388010/0001193125-26-388010-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}